Epidemiological studies show that patients with type 2 diabetes (T2DM) and individuals with a diabetes-independent elevation in blood glucose have an increased risk for developing dementia, specifically dementia due to Alzheimer's disease (AD). These observations suggest that abnormal glucose metabolism likely plays a role in some aspects of AD pathogenesis, leading us to investigate the link between aberrant glucose metabolism, T2DM, and AD in murine models. Here, we combined two techniquesglucose clamps and in vivo microdialysis -as a means to dynamically modulate blood glucose levels in awake, freely moving mice while measuring real-time changes in amyloidb (Ab), glucose, and lactate within the hippocampal interstitial fluid (ISF). In a murine model of AD, induction of acute hyperglycemia in young animals increased ISF Ab production and ISF lactate, which serves as a marker of neuronal activity. These effects were exacerbated in aged AD mice with marked Ab plaque pathology. Inward rectifying, ATP-sensitive potassium (K ATP ) channels mediated the response to elevated glucose levels, as pharmacological manipulation of K ATP channels in the hippocampus altered both ISF Ab levels and neuronal activity. Taken together, these results suggest that K ATP channel activation mediates the response of hippocampal neurons to hyperglycemia by coupling metabolism with neuronal activity and ISF Ab levels.
Introduction
The aggregation and subsequent cerebral accumulation of the amyloid-β (Aβ) peptide is a key initiating factor in Alzheimer's disease (AD), where Aβ aggregation begins approximately 15 years prior to the onset of cognitive symptoms (1, 2) . In addition to extracellular Aβ aggregation and subsequently intraneuronal tau accumulation, decreased glucose metabolism also occurs in regions prone to AD pathology during this presymptomatic period. Although both Aβ and tau are central to AD pathogenesis, it is unclear whether glucose dysregulation is an initiator of AD pathology, a secondary consequence of neuronal dysfunction due to Aβ and tau deposition, or both. Recent epidemiological studies demonstrate that individuals with type 2 diabetes (T2DM) are 2-4 times more likely to develop AD (3) (4) (5) , individuals with elevated blood glucose levels are at an increased risk to develop dementia (5) , and those with elevated blood glucose levels have a more rapid conversion from mild cognitive impairment (MCI) to AD (6) , suggesting that disrupted glucose homeostasis could play a more causal role in AD pathogenesis. Although several prominent features of T2DM, including increased insulin resistance and decreased insulin production, are at the forefront of AD research (7) (8) (9) (10) , questions regarding the effects of elevated blood glucose independent of insulin resistance on AD pathology remain largely unexplored. In order to investigate the potential role of glucose metabolism in AD, we combined glucose clamps and in vivo microdialysis as a method to measure changes in brain metabolites in awake, freely moving mice during a hyperglycemic challenge. Our findings suggest that acute hyperglycemia raises interstitial fluid (ISF) Aβ levels by altering neuronal activity, which increases Aβ production. Since cerebral glucose metabolism is tightly linked to neuronal activity (11, 12) and elevated neuronal activity increases Aβ production (13) (14) (15) , we explored the role of inward rectifying, ATP-sensitive potassium (K ATP ) channels as one mechanism linking glucose metabolism, neuronal excitability, and ISF Aβ. Our data suggests that K ATP channels can mediate the response of hippocampal neurons to elevated blood glucose levels by coupling changes in metabolism with neuronal activity and ISF Aβ.
Results and Discussion
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Number 6 June 2015 PS1 mice where blood glucose was clamped between 150-200 mg/dl, increases in blood glucose raised ISF glucose 2.6-fold from baseline ( Figure 1E ). Hyperglycemia significantly increased hippocampal ISF Aβ by 38.8% ± 5.3%, with a maximal effect of 45.6% ± 9.0%, which persisted after euglycemia was restored ( Figure 1F ). The hyperglycemia-dependent increase in ISF Aβ levels was 1.6-fold higher in 18-month-old mice compared with 3-monthold mice, demonstrating that older mice with significant plaque pathology respond differentially to a hyperglycemic insult. Previous studies demonstrated that increased synaptic activity drives Aβ release from an endocytic pool in vivo, resulting in an increase in ISF Aβ but not total tissue Aβ (14, 15, 18) . We found that hyperglycemia increased ISF Aβ specifically, while the total amount of Aβ 40 and Aβ 42 within the brain did not change (Supplemental Figure 3) . Due to the astrocyte neuron lactate shuttle, extracellular lactate can be used as a marker of neuronal activity, and previous work shows that it increases in concert with ISF Aβ (13, (20) (21) (22) . ISF lactate increased during glucose clamps, suggesting hyperglycemia increases both neuronal activity and ISF Aβ ( Figure 1G and Supplemental Figure 4) . To determine whether elevations in ISF Aβ were due to increased production or decreased clearance of Aβ, we administered compound E, a potent gamma secretase inhibitor, concurrently with hyperglycemia as a means to abolish Aβ production and to measure the rate of ISF Aβ clearance. This showed that the rate of ISF Aβ clearance did not differ in the presence versus the absence of hyperglycemia, illustrating that the hyperglycemia-induced increase in ISF Aβ levels is not due to a significant in blood glucose resulted in a 1.9-fold increase in hippocampal ISF glucose ( Figure 1B ). ISF Aβ increased by 24.5% ± 3.8% during the hyperglycemia challenge, an effect that was sustained after euglycemia was restored subsequent to the glucose clamp (Figure 1C) . While the effects of glucose on ISF Aβ were variable, ISF glucose correlated with ISF Aβ during hyperglycemia (Pearson's r = 0.6032; P < 0.01), demonstrating that hippocampal Aβ concentrations are likely modulated by blood glucose levels ( Figure 1D) .
Hypothesizing that the presence of Aβ aggregation into amyloid plaques and oligomers promotes localized injury and affects the brain's response to hyperglycemia, we altered blood glucose levels in mice with significant Aβ plaque burden (Supplemental Figure 2 ). Using the same approach in 18-month-old APP/ Figure 5A ), diazoxide decreased ISF lactate by 22.5% ± 4.3%, suggesting an inhibitory effect on neuronal activity ( Figure 2D ). This finding is consistent with previous work, demonstrating that diazoxide decreased action-potential frequency and calcium influx in cultured cortical neurons (26) . Together, our findings suggest that K ATP channels alter cellular excitability within the hippocampus and that increased cellular excitability via K ATP channel activation leads to increased ISF Aβ.
To determine whether increases in ISF Aβ during hyperglycemia were due to K ATP channels, we investigated whether opening K ATP channels prevented increases in ISF Aβ during hyperglycemia. Diazoxide was infused into the hippocampus via reverse microdialysis prior to and during hyperglycemia in 18-month-old APP/PS1 mice. ISF Aβ levels did not significantly change prior to and during hyperglycemia in the presence of diazoxide ( Figure 3A) . In contrast, hyperglycemia alone resulted in a 38.8% ± 5.3% elevation in ISF Aβ, demonstrating that diazoxide blocks the increase in ISF Aβ during hyperglycemia ( Figure 3A) . Using ISF lactate levels as a measure of neuronal activity, diazoxide treatment blocked the hyperglycemiadependent increase in ISF lactate levels ( Figure 3B ). Taken together, these findings demonstrate that K ATP channel activation mediates the response of hippocampal neurons to elevated glucose levels by coupling metabolism with neuronal activity and ISF Aβ.
By combining glucose clamps with in vivo microdialysis, we were able to modulate blood glucose levels in awake, freely moving APP/PS1 mice while simultaneously investigating slowing of Aβ clearance ( Figure 1H ). Since both T2DM and AD are diseases of aging and Aβ deposition begins about 15 years prior to the onset of dementia due to AD, these findings suggest that poor glycemic control during a presymptomatic period could increase basal neuronal activity, drive Aβ production/release, and instigate or exacerbate Aβ deposition.
Elevated extracellular glucose levels can evoke rapid changes in neuronal excitability through K ATP channels (23, 24) . K ATP channels are hetero-octameric proteins composed of 4 inner poreforming subunits (Kir6.1 or Kir6.2) and 4 sulfonylurea receptor (SUR) subunits. Increased glucose concentrations lead to elevations in intracellular ATP, causing K ATP channel closure, membrane depolarization, and increased cellular excitability. Although best described for their role in insulin secretion in pancreatic β cells, K ATP channels are found on both neurons and astrocytes (25) and can couple cellular metabolism with neuronal activity. To investigate the role of K ATP channel activity on glucose-dependent increases in ISF Aβ, we pharmacologically manipulated hippocampal K ATP channels under euglycemic and hyperglycemic conditions. We delivered glibenclamide, a K ATP channel antagonist, to the APP/PS1 hippocampus via reverse microdialysis and found that it increased ISF Aβ and lactate levels in a dose-dependent manner, with a maximal effect of 36.2% ± 3.2% and 73.3% ± 19.8%, respectively ( Figure 2, A and B) . These findings illustrate that closure of K ATP channels leads to both increased neuronal activity and extracellular concentrations of Aβ (Figure 2, A andB) . Conversely, we investigated whether the K ATP channel agonists, diazoxide and pinacidil, affect ISF Aβ and lactate levels by opening K ATP channels Figure 3 . Pharmacological manipulation of K ATP channels blocks hyperglycemia-induced increases in ISF Aβ. (A) In 18-month-old APP/PS1 mice, glucose clamps increase ISF Aβ. However, when diazoxide, a K ATP agonist, is given via reverse microdialysis during hyperglycemia, the increase in ISF Aβ is blocked (38.84% ± 3.5% vs. 9.33% ± 2.1% increase). (B) Treatment with diazoxide decreased hippocampal ISF lactate in 18-month-old APP/PS1 mouse brains during hyperglycemia, suggesting decreased neuronal activity coincides with decreased ISF Aβ (11.8% ± 3.6% vs. -4.043% ± 3.4%). Data represent mean ± SEM. For all analyses, n = 6-7 mice/group, *P < 0.05, ***P < 0.001 using 2-way ANOVA. changes in Aβ, glucose, and lactate within the hippocampal ISF. Our data demonstrate that elevated blood glucose levels affect hippocampal metabolism, neuronal activity, and ISF Aβ concentrations in young mice, lacking any appreciable Aβ plaque load. However, in aged mice with marked Aβ deposition, the effect of hyperglycemia on ISF Aβ is exacerbated, suggesting that ageor pathology-dependent changes result in an alteration of the brain's response to a metabolic insult. Since extracellular Aβ, and subsequently tau, aggregate in a concentration-dependent manner during the preclinical period of AD while individuals are cognitively normal (27) , our findings suggest that repeated episodes of transient hyperglycemia, such as those found in T2DM, could both initiate and accelerate plaque accumulation. Thus, the correlation between hyperglycemia and increased ISF Aβ provides one potential explanation for the increased risk of AD and dementia in T2DM patients or individuals with elevated blood glucose levels. In addition, our work suggests that K ATP channels within the hippocampus act as metabolic sensors and couple alterations in glucose concentrations with changes in electrical activity and extracellular Aβ levels. Not only does this offer one mechanistic explanation for the epidemiological link between T2DM and AD, but it also provides a potential therapeutic target for AD. Given that FDA-approved drugs already exist for the modulation of K ATP channels and previous work demonstrates the benefits of sulfonylureas for treating animal
